FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971218335> ?p ?o ?g. }

• W2971218335 endingPage "4549" @default.
• W2971218335 startingPage "4549" @default.
• W2971218335 abstract "Abstract Background VOD/SOS is a potentially life-threatening complication of HSCT conditioning, with a reported mean incidence of 13.7%. VOD/SOS with multi-organ dysfunction (MOD) may be associated with >80% mortality. Defibrotide is approved for treatment of hepatic VOD/SOS with renal/pulmonary dysfunction post-HSCT in the United States and for treating severe hepatic VOD/SOS post-HSCT in the European Union. The defibrotide expanded-access program (T-IND) was designed to provide access to defibrotide prior to its approval in the US and to collect data on safety and efficacy. There are few published data on survival of patients with neuroblastoma who develop VOD/SOS. Here, Day +100 post-HSCT survival and safety are analyzed post hoc for the subgroup of patients in that study with a primary disease of neuroblastoma. Methods The T-IND was the largest prospective study of defibrotide. The original protocol required VOD/SOS diagnosis by Baltimore criteria (bilirubin ≥2 mg/dL and ≥2 of: hepatomegaly, ascites, ≥5% weight gain) or biopsy, post-HSCT, with evidence of MOD. The study was amended to also include patients without MOD (off label), with VOD/SOS per modified Seattle criteria (≥2 of: bilirubin >2 mg/dL, hepatomegaly, or ≥5% weight gain [in this study]), and/or with VOD/SOS following chemotherapy without HSCT (off label). Patients received defibrotide 25 mg/kg/d in 4 divided doses (6.25 mg/kg q6h), which was recommended for ≥21 days. Results This post hoc analysis of final data is based on 1154 patients enrolled from 2007-2016 who received ≥1 dose of defibrotide, including 571 patients with MOD. The primary diseases affecting 5% or more of the safety population at baseline were acute myelogenous leukemia, 24.2% (n=279); acute lymphocytic leukemia, 24.2% (n=279); and neuroblastoma, 9.6% (n=111). Among patients with neuroblastoma, 106 had received HSCT and 5 had chemotherapy without HSCT. In the post-HSCT subgroup, 64 (60.4%) were male and 42 (39.6%) were female, median age was 3 years (range 1-17 years), with 7.6% aged 0-23 months, 90.6% aged 2-11 years, 0.9% aged 12-16 years, and 1 (0.9%) patient was aged >16 years at HSCT. At Day +100 post-HSCT, survival data were available for 105 of the 106 neuroblastoma patients treated with defibrotide with documented VOD/SOS, 43 with MOD and 62 without MOD. Of these patients, 103 had autologous transplants and 2 had allogeneic transplants. Kaplan-Meier estimated Day +100 survival for the total neuroblastoma group was 87.2% (95% confidence interval [CI], 79.0%-92.4%; Fig). For the MOD subgroup, Kaplan-Meier estimated Day +100 survival was 78.4% (95% CI, 62.6%-88.2%), and for the subgroup without MOD, 93.5% (95% CI, 83.6%-97.5%). For comparison, in the subgroup aged ≤16 years of the overall HSCT population (n=570; 127 autologous), Kaplan-Meier estimated Day +100 survival was 67.9% (95% CI, 63.8%-71.6%; Fig;Richardson PG et al. European Hematology Association 2017. Abstract P748). Adverse events (AEs) occurred in 45.3% (48/106) of neuroblastoma patients, with serious AEs in 23.6% (25/106; most common: multi-organ failure, 4.7% [5/106]). AEs leading to discontinuation developed in 17.0% (18/106) (most common: pulmonary hemorrhage, 2.8% [3/106]); death occurred in 10.4% (11/106) (>2%: multi-organ failure, 4.7% [5/106]; veno-occlusive disease, 2.8% [3/106]). Treatment-related AEs, as assessed by the investigators and of any severity, occurred in 17.0% (18/106) of neuroblastoma patients (most common: pulmonary hemorrhage, 2.8% [3/106]). Conclusions There are few data on VOD/SOS outcomes in patients with neuroblastoma. This post hoc analysis of final data from the defibrotide expanded-access study found Kaplan-Meier estimated Day +100 survival of 87.2% in the comparatively large group of patients with a primary disease of neuroblastoma and VOD/SOS following HSCT (primarily autologous). Day +100 Kaplan-Meier estimated survival rates were 78.4% and 93.5% in the neuroblastoma groups with and without MOD, respectively. The Day +100 safety profile for the neuroblastoma subgroup in the expanded-access program was consistent with prior defibrotide studies and analyses of the overall HSCT population in this study. These findings provide supportive evidence for, and warrant additional studies into, the clinical utility of defibrotide for treatment of VOD/SOS in patients receiving HSCT for this common pediatric solid tumor. Support: Jazz Pharmaceuticals. Download : Download high-res image (103KB) Download : Download full-size image Disclosures Grupp: University of Pennsylvania: Patents & Royalties; Adaptimmune: Consultancy; Jazz Pharmaceuticals: Consultancy; Novartis Pharmaceuticals Corporation: Consultancy, Other: grant. Ryan: Celator/Jazz: Employment, Equity Ownership. Hume: Jazz Pharmaceuticals, Inc.: Employment, Other: stock options. Tappe: Jazz Pharmaceuticals, Inc.: Employment, Other: stock options. Richardson: Oncopeptides AB: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2971218335 created "2019-09-05" @default.
• W2971218335 creator A5009930475 @default.
• W2971218335 creator A5011524144 @default.
• W2971218335 creator A5020759638 @default.
• W2971218335 creator A5022882979 @default.
• W2971218335 creator A5031745226 @default.
• W2971218335 creator A5043526996 @default.
• W2971218335 creator A5072449563 @default.
• W2971218335 creator A5077440294 @default.
• W2971218335 date "2017-12-07" @default.
• W2971218335 modified "2023-09-28" @default.
• W2971218335 title "Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Neuroblastoma: Final Data from the Defibrotide Expanded-Access Program" @default.
• W2971218335 doi "https://doi.org/10.1182/blood.v130.suppl_1.4549.4549" @default.
• W2971218335 hasPublicationYear "2017" @default.
• W2971218335 type Work @default.
• W2971218335 sameAs 2971218335 @default.
• W2971218335 citedByCount "0" @default.
• W2971218335 crossrefType "journal-article" @default.
• W2971218335 hasAuthorship W2971218335A5009930475 @default.
• W2971218335 hasAuthorship W2971218335A5011524144 @default.
• W2971218335 hasAuthorship W2971218335A5020759638 @default.
• W2971218335 hasAuthorship W2971218335A5022882979 @default.
• W2971218335 hasAuthorship W2971218335A5031745226 @default.
• W2971218335 hasAuthorship W2971218335A5043526996 @default.
• W2971218335 hasAuthorship W2971218335A5072449563 @default.
• W2971218335 hasAuthorship W2971218335A5077440294 @default.
• W2971218335 hasConcept C126322002 @default.
• W2971218335 hasConcept C141071460 @default.
• W2971218335 hasConcept C2775832928 @default.
• W2971218335 hasConcept C2777408962 @default.
• W2971218335 hasConcept C2777712501 @default.
• W2971218335 hasConcept C2780496750 @default.
• W2971218335 hasConcept C2780895475 @default.
• W2971218335 hasConcept C2911091166 @default.
• W2971218335 hasConcept C71924100 @default.
• W2971218335 hasConcept C90924648 @default.
• W2971218335 hasConceptScore W2971218335C126322002 @default.
• W2971218335 hasConceptScore W2971218335C141071460 @default.
• W2971218335 hasConceptScore W2971218335C2775832928 @default.
• W2971218335 hasConceptScore W2971218335C2777408962 @default.
• W2971218335 hasConceptScore W2971218335C2777712501 @default.
• W2971218335 hasConceptScore W2971218335C2780496750 @default.
• W2971218335 hasConceptScore W2971218335C2780895475 @default.
• W2971218335 hasConceptScore W2971218335C2911091166 @default.
• W2971218335 hasConceptScore W2971218335C71924100 @default.
• W2971218335 hasConceptScore W2971218335C90924648 @default.
• W2971218335 hasLocation W29712183351 @default.
• W2971218335 hasOpenAccess W2971218335 @default.
• W2971218335 hasPrimaryLocation W29712183351 @default.
• W2971218335 hasRelatedWork W2025891049 @default.
• W2971218335 hasRelatedWork W2302063530 @default.
• W2971218335 hasRelatedWork W2342148351 @default.
• W2971218335 hasRelatedWork W2531016723 @default.
• W2971218335 hasRelatedWork W2560189518 @default.
• W2971218335 hasRelatedWork W2566394954 @default.
• W2971218335 hasRelatedWork W2570676655 @default.
• W2971218335 hasRelatedWork W2576088627 @default.
• W2971218335 hasRelatedWork W2593577562 @default.
• W2971218335 hasRelatedWork W2772591646 @default.
• W2971218335 hasRelatedWork W2783899460 @default.
• W2971218335 hasRelatedWork W2803440649 @default.
• W2971218335 hasRelatedWork W2805170187 @default.
• W2971218335 hasRelatedWork W3097311411 @default.
• W2971218335 hasRelatedWork W3127939395 @default.
• W2971218335 hasRelatedWork W3132459625 @default.
• W2971218335 hasRelatedWork W3135599149 @default.
• W2971218335 hasRelatedWork W3154182502 @default.
• W2971218335 hasRelatedWork W3169323847 @default.
• W2971218335 hasRelatedWork W3207637480 @default.
• W2971218335 hasVolume "130" @default.
• W2971218335 isParatext "false" @default.
• W2971218335 isRetracted "false" @default.
• W2971218335 magId "2971218335" @default.
• W2971218335 workType "article" @default.